Stocktoria
NEXGEL, INC. NXGL
NEXGEL, INC. (NXGL) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $11.4M at a -26.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.47 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.132 |
| Retained earnings / assets | -2.007 |
| EBIT / assets | -0.32 |
| Equity / liabilities | 0.878 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NXGL | NEXGEL, INC. | 5/9 | -6.91 | — | — |
| WOK | WORK Medical Technology Group LTD | 4/9 | — | — | -14.4% |
| MDNC | Medinotec Inc. | 5/9 | — | 74 | — |
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | 5/9 | -19.57 | — | — |
| NSPR | InspireMD, Inc. | 3/9 | -10.12 | — | — |
| XAIR | Beyond Air, Inc. | 5/9 | — | — | — |
| IVF | INVO Fertility, Inc. | 4/9 | -19.01 | — | — |
About NEXGEL, INC.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
FAQ
Is NXGL financially healthy?
NEXGEL, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NXGL pay a dividend?
No, NEXGEL, INC. does not currently pay a dividend.
How profitable is NXGL?
In FY2025, NEXGEL, INC. had a net margin of -26.3% and a return on equity of -61.3%.
What is the analyst price target for NXGL?
The average Wall-Street price target for NEXGEL, INC. is $2.00, about 386.7% above the recent price, from 1 analysts.
Is NXGL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEXGEL, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.